Experts Welcome Adjuvant Nivolumab for Melanoma Experts Welcome Adjuvant Nivolumab for Melanoma

The PD-1 inhibitor nivolumab was recently approved by the FDA for adjuvant use in completely resected stage III or IV melanoma, a move welcomed by experts in the field.Medscape Medical News

Source: Medscape Medical News Headlines - January 19, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news